Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities (2017 - 2025)
Rhythm Pharmaceuticals (RYTM) reported Total Non-Current Liabilities of $210.2 million for Q4 2025, down 7.71% year-over-year from $227.7 million in Q4 2024, and down 7.71% on a QoQ basis from $227.7 million in Q4 2024.
Rhythm Pharmaceuticals (RYTM) has 5 years of Total Non-Current Liabilities data on file, last reported at $210.2 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 7.71% year-over-year to $210.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $210.2 million (down 7.71% YoY) and the FY2025 annual result came in at $210.2 million, down 7.71% from the prior year.
- Total Non-Current Liabilities declined to $210.2 million in Q4 2025 per RYTM's latest filing, from $227.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $227.7 million in Q4 2024 and bottomed at $80.5 million in Q2 2022.
- The 4-year median for Total Non-Current Liabilities is $155.5 million (2023), against an average of $152.3 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities soared 57.03%; it then slipped 7.71% in 2025.
- Tracing RYTM's Total Non-Current Liabilities over 4 years: stood at $116.9 million in 2022, then soared by 38.46% to $161.8 million in 2023, then soared by 40.71% to $227.7 million in 2024, then dropped by 7.71% to $210.2 million in 2025.
- Per Business Quant, the three latest RYTM Total Non-Current Liabilities figures stand at $210.2 million (Q4 2025), $227.7 million (Q4 2024), and $166.8 million (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Rhythm Pharmaceuticals | 6.00 Bn | 5.66 Bn | 52.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 210.17 Mn |
| Dec 31, 2024 | 227.72 Mn |
| Jun 30, 2024 | 166.76 Mn |
| Mar 31, 2024 | 196.41 Mn |
| Dec 31, 2023 | 161.84 Mn |
| Sep 30, 2023 | 155.54 Mn |
| Jun 30, 2023 | 126.34 Mn |
| Mar 31, 2023 | 125.91 Mn |
| Dec 31, 2022 | 116.88 Mn |
| Sep 30, 2022 | 107.50 Mn |
| Jun 30, 2022 | 80.46 Mn |
| Sep 30, 2017 | 5.38 Mn |